Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX)
Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 735,888 | $288,203,176 | -27% | 0.38% |
| 2. | Squarepoint Ops LLC Maxime Fortin (Cio) | 607,836 | $238,052,891 | +246% | 0.24% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 482,495 | $188,964,342 | +171% | 0.3% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 381,195 | $149,291,210 | +521% | 0.09% |
| 5. | GLG Partners Noam Gottesman | 362,774 | $142,076,809 | +185% | 0.25% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $389.95 | 5,710 | $2,226,614.50 | 115,968 | 2025-08-06 | Filing | |
| $389.08 | 4,290 | $1,669,153.20 | 110,258 | 2025-08-06 | Filing | |
| $389.84 | 3,366 | $1,312,201.44 | 45,000 | 2025-08-06 | Filing | |
| $389.36 | 1,634 | $636,214.24 | 41,634 | 2025-08-06 | Filing | |
| $196.34 | 4,243 | $833,070.62 | 73,754 | 2021-08-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $461.00 | 7,000 | $3,227,000.00 | 37,725 | 2025-12-03 | Filing | |
| $451.00 | 7,000 | $3,157,000.00 | 44,725 | 2025-12-03 | Filing | |
| $449.99 | 4,500 | $2,024,955.00 | 46,793 | 2025-12-03 | Filing | |
| $455.22 | 2,070 | $942,305.40 | 24,026 | 2025-12-03 | Filing | |
| $453.34 | 10,360 | $4,696,602.40 | 26,096 | 2025-12-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 25,910,587 | $10,147,738,320 | 1.39% | |
| 2. | 24,216,865 | $9,484,293,009 | 0.14% | |
| 3. | 22,253,047 | $8,715,183,579 | 0.15% | |
| 4. | 16,553,281 | $6,482,977,895 | 1.22% | |
| 5. | 11,606,000 | $4,545,373,840 | 0.16% |
News See All
What Do Analysts Think About Vertex Pharmaceuticals (VRTX)?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best large cap stocks to invest in for the long term.
13 Best Large Cap Stocks to Invest in For the Long Term
Pies does not see anything fundamentally broken in today’s markets and stated that if we go through our checklist, we can see that a recession does not seem imminent.
Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds.
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q3 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q3 2025 Earnings Call Transcript November 3, 2025Vertex Pharmaceuticals Incorporated beats earnings expectations.
H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Bank of America Securities Remains Bullish on Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best long term low volatility stocks to buy right now.
14 Best Long Term Low Volatility Stocks to Buy Right Now
Mike Wilson, Morgan Stanley CIO and chief U.S.
Hedge Fund Resource Center Billionaire Hedge Funds
